Rate My Professor Bin Yang

Bin Yang's research centers on the mechanisms, diagnosis, and intervention of acute kidney injury (AKI) and its progression to chronic kidney disease in native and transplant kidneys. Core interests include cellular processes of injury such as apoptosis, necrosis, inflammation, innate and adaptive immunity; kidney repair through remodeling, recovery, or fibrosis; gene expression profiling for biomarkers like SERPINA3 and SLPI, validated in human plasma and urine; gene therapy approaches including CASP3 siRNA; and renoprotection via erythropoietin derivatives such as HBSP and CHBP. He utilizes isolated kidney perfusion systems and siRNA delivery targeting the EPO receptor/β common receptor. Recent grants include £982,618 from the Medical Research Council (2025-2028) for 'A Precise Therapy for Acute Kidney Injury by Delivering CASP3 siRNA Conjugated with Peptide Ligand Target Innate Repair Receptor Expressing Cells'; £10,000 from Kidney Care Appeal (2024-2025 and 2023-2024); £35,138 from van Geest Foundation (2022-2023); and £57,000 from the National Natural Science Foundation of China (2019-2022). Key publications encompass 'Co-treatment with erythropoietin derived HBSP and caspase-3 siRNA: A promising approach to prevent fibrosis after acute kidney injury' (J Cell Mol Med, 2024), 'HBSP inhibits tubular cell pyroptosis and apoptosis, promotes macrophage M2 polarization, and protects LPS-induced acute kidney injury' (J Cell Mol Med, 2024), 'HBSP improves kidney ischemia-reperfusion injury and promotes repair in properdin deficient mice' (Front Immunol, 2023), and 'Serum-stabilized naked caspase-3 siRNA protects autotransplant kidneys in a porcine model' (Mol Ther, 2014). With over 2,700 citations, his contributions advance innate immunity roles in kidney injury, repair, and fibrosis.